PHILADELPHIA (AP) — A U.S. health panel says it’s time to resume use of Johnson & Johnson’s COVID-19 vaccine, despite a very rare risk of blood clots. Out of nearly 8 million people vaccinated before the U.S. suspended J&J’s shot, health officials uncovered 15 cases of a highly unusual kind of blood clot, three of them fatal.
All were women, most younger than 50.READ MORE: Giant Supermarket Chain Opening 4 New Stores In Philadelphia, Hiring 700 Employees
But advisers to the Centers for Disease Control and Prevention said Friday the vaccine’s benefits outweigh that serious but small risk — especially against a virus that’s still infecting tens of thousands of Americans every day.READ MORE: Philadelphia Officials Expected To Provide Update On Reopening Timeline Tuesday, Sources Say
The government will rapidly weigh that recommendation in deciding next steps.MORE NEWS: 13-Year-Old Among Injured In Allentown Triple Shooting
(Copyright 2021 by The Associated Press. All Rights Reserved.)